Notice of Results

RNS Number : 3290N

Creo Medical Group PLC

23 September 2019

 

Creo Medical Group plc

("Creo" or the "Company")

Notice of results

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, will announce its interim results for the six months ended 30 June 2019 on Monday, 30 September 2019.

Creo Medical Group plc	investors.creomedical.com
Richard Rees (CFO)	[phone]
Cenkos Securities	[phone]
Stephen Keys / Cameron MacRitchie
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiofrequency energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar RF for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes that its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

 

END

 

 

NORXXLFLKKFFBBZ